Prescribing guide
Zavesca (miglustat)Dosing, renal dose adjustment, neurological and platelet monitoring and prior authorization criteria for type 1 Gaucher diseaseFor prescribers and their offices treating gaucher disease: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS, no boxed warning, no contraindications. Baseline neurological evaluation, a starting dose set by adjusted creatinine clearance, prior authorization and specialty pharmacy dispensing before the first fill.
Example PA threshold
Cigna example: documented deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts, or biallelic pathogenic GBA variants; not for neurological manifestations; specialist prescriber; generic miglustat before brand Zavesca; no concurrent Gaucher therapy.
Monitoring
Neurological evaluation at baseline and about every 6 months in all patients; platelet counts recommended; watch tremor, diarrhea and weight; renal function where it may be reduced.
Support line
No manufacturer support, copay or free drug program is published on zavesca.com; Janssen 1-800-526-7736; Accredo can ship at the prescriber's direction; the specialty pharmacy calls monthly about refills.
Give your patient their plan
A one-page handout for starting Zavesca, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/zavescaBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Confirm the labeled population | Monotherapy for adults with mild to moderate type 1 Gaucher disease for whom ERT is not a therapeutic option (e.g. allergy, hypersensitivity or poor venous access). Therapy should be directed by physicians knowledgeable in Gaucher disease. | FDA label |
| Baseline neurological evaluation | Required at baseline in all patients, then at approximately 6-month intervals. | FDA label |
| Renal function | Adjusted creatinine clearance sets the starting dose; not recommended below 30mL/min/1.73m². | FDA label |
| Counsel before the first dose | Peripheral neuropathy, tremor, diarrhea and dietary instructions, weight loss, platelet reductions, fetal risk based on animal data, no breastfeeding, and the missed-dose rule. | FDA label |
| Brand or generic | The Cigna policy covers generic miglustat, Yargesa and Zavesca under the same criteria and requires a trial of the bioequivalent generic before brand Zavesca. | Cigna policy |
| Route the prescription | The Zavesca site states it is not available at local pharmacies; Accredo can ship at the prescriber's direction, and the specialty pharmacy calls the patient monthly to confirm delivery and arrange the refill. | Zavesca patient resources |
| Package | 100mg capsules in blister cards, 6 cards of 15 per carton (90 capsules, NDC 66215-201-90). 30 days at three times a day. Store at 20°C to 25°C. The package is not child resistant. | FDA label |
| Manufacturer support | The Zavesca patient pages name no hub, copay or patient assistance program. Contact listed: Janssen, 1-800-526-7736. | Zavesca contact page |
Prior authorization criteria and what to document
One public policy as the example: Cigna, July 15, 2026. Approval one year. This policy (Drug Coverage Policy IP0446) covers generic miglustat, Yargesa and Zavesca, and it cites the August 2022 Zavesca label, the current text. In 2024 Cigna removed its criteria on age, use alone and whether enzyme replacement is possible, although the label still limits Zavesca to adults who cannot use enzyme replacement. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis, enzyme route | Deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts [documentation required] | Enzyme assay report | Cigna policy |
| Diagnosis, genetic route | Molecular genetic test showing biallelic pathogenic GBA variants [documentation required]; either route qualifies | Genetic test report | Cigna policy |
| Type | Gaucher disease type 1; criteria on age, monotherapy and ability to take ERT were removed in 2024 | Diagnosis in the note | Cigna policy |
| Use | Not for management of neurological manifestations (examples: abnormal ocular movement, auditory impairment, cognitive impairment, seizures); added July 15, 2026 | Treatment goals in the note | Cigna policy |
| Prescriber | Geneticist, endocrinologist, metabolic disorder subspecialist or a physician who specializes in Gaucher disease or related disorders, or in consultation with one | Prescriber specialty or consult note | Cigna policy |
| Brand Zavesca | Tried bioequivalent generic miglustat and cannot take it because of an inactive ingredient difference that would, per the prescriber, cause a significant allergy or serious adverse reaction | Dates of the generic trial and the reaction or ingredient at issue | Cigna policy |
| Concurrent therapy | Not medically necessary with Cerezyme, Elelyso, Vpriv or Cerdelga | Current medication list | Cigna policy |
| Approval | 1 year | Updated criteria at each review | Cigna policy |
Zavesca dosing and titration
| When | Label | Source |
|---|---|---|
| Recommended dose | One 100mg capsule orally three times a day at regular intervals. | FDA label |
| Adverse reactions | It may be necessary to reduce to 100mg once or twice a day in some patients, for example for tremor or diarrhea. | FDA label |
| Mild renal impairment | Adjusted creatinine clearance 50 to 70mL/min/1.73m²: start at 100mg twice a day. | FDA label |
| Moderate renal impairment | Adjusted creatinine clearance 30 to 50mL/min/1.73m²: start at 100mg once a day. | FDA label |
| Severe renal impairment | Creatinine clearance below 30mL/min/1.73m²: use is not recommended. Hemodialysis not investigated. | FDA label |
| Missed dose | Take the next capsule at the next scheduled time. | FDA label |
| Food | Food lowers Cmax by 36% and delays tmax by 2 hours, with no statistically significant effect on AUC (down 14%). Diarrhea may respond to taking Zavesca between meals. | FDA label |
| Geriatric | Insufficient numbers aged 65 and over in studies; select the dose cautiously and consider monitoring renal function. | FDA label |
| Pediatric, hepatic | Safety and effectiveness not established in pediatric patients. No pharmacokinetic studies in hepatic impairment. | FDA label |
Monitoring the Zavesca label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Baseline, then about every 6 months | Neurological evaluation, all patients | Peripheral neuropathy in 3% of Gaucher patients in trials. With pain, weakness, numbness or tingling, reassess risk and benefit; cessation may be considered | FDA label |
| First month onward | Tremor or exacerbation of existing tremor, about 30% | Usually began in the first month and in many cases resolved between 1 and 3 months. Reduce the dose; discontinue if it does not resolve within days of dose reduction | FDA label |
| Ongoing | Diarrhea, about 85% | May respond to reduced sucrose, lactose and other carbohydrate intake, dosing between meals, or anti-diarrheals, most commonly loperamide. If persistent and unresponsive, evaluate for underlying gastrointestinal disease | FDA label |
| Ongoing, most evident in the first 12 months | Weight loss, up to 65% | Cause unclear (diarrhea, reduced intake or both). Not evaluated in significant gastrointestinal disease such as inflammatory bowel disease; weigh risks and benefits of continuing | FDA label |
| Ongoing | Platelet count | Monitoring recommended in type 1 Gaucher disease. Mild reductions without bleeding were seen, including in patients switched from ERT | FDA label |
| Elderly or reduced renal function | Renal function | Substantially renally excreted; risk of adverse reactions may be greater with impaired renal function | FDA label |
Zavesca drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Contraindications | None | FDA label |
| Imiglucerase | Co-administration appeared to increase imiglucerase clearance by 70%; not conclusive (few patients, variable imiglucerase doses). Zavesca is indicated as monotherapy | FDA label |
| Other Gaucher therapies | Concurrent Cerezyme, Elelyso, Vpriv or Cerdelga is not medically necessary under the Cigna policy | Cigna policy |
| Pregnancy | May cause fetal harm based on animal data (embryo-fetal toxicity in rats at 2 times the human dose; maternal toxicity in rabbits near the human dose). Postmarketing reports insufficient to assess risk. Advise patients to report a known or suspected pregnancy | FDA label |
| Lactation | No data on presence in milk; likely present based on physical properties. Breastfeeding not recommended | FDA label |
| Male fertility | No effect indicated in 7 healthy men over 6 weeks. In male rats, sperm effects and decreased fertility at all doses (lowest 0.65 times the human dose), reversible after 6 weeks off drug | FDA label |
| Label history | Sections 8.1 to 8.3 were converted to Pregnancy and Lactation Labeling Rule format in December 2020 (S-016) | FDA letter |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe Cigna policy below asks for a report showing low enzyme activity in white blood cells or skin cells, or a genetic test showing changes in both GBA genes.
- The plan wants generic miglustat firstFor brand Zavesca, Cigna asks that the generic be tried first. It then asks that an inactive ingredient difference would cause a significant allergy or serious reaction, per the prescriber.
- The doctor is not a specialistCigna asks that miglustat be prescribed by, or with advice from, a geneticist, endocrinologist, metabolic disorder specialist or a physician who specializes in Gaucher disease.
- The request mentions brain or nerve symptomsCigna does not approve miglustat for Gaucher disease when it is used to manage neurological symptoms such as seizures or abnormal eye movement.
- Also taking another Gaucher medicineCigna treats miglustat used together with Cerezyme, Elelyso, Vpriv or Cerdelga as not medically necessary. The label also approves Zavesca only as monotherapy.
- The local pharmacy cannot fill itZavesca's site says it is not available at your local pharmacy. Accredo, a specialty pharmacy, can ship it at the direction of your doctor.
- A copay you cannot payZavesca's site names no copay card or free drug program. Its contact page lists Janssen at 1-800-526-7736.
Janssen, no Zavesca patient support program published
- Zavesca's contact page lists this number, 1-800-Janssen, and the label gives it for more information and for reporting side effects
- Accredo, a specialty pharmacy, can ship Zavesca at the direction of your doctor. The specialty pharmacy calls each month to confirm delivery and arrange the refill Zavesca patient resources
- A Healthy Choices guide on managing diet while taking Zavesca, free to download Healthy Choices guide
- Zavesca's patient pages name no copay card, bridge supply or free drug program Zavesca patient resources
- For more help, Zavesca's site points to the National Gaucher Foundation at 1-800-504-3189 About Zavesca
Questions prescribers' offices ask about Zavesca
What is the Zavesca dose for type 1 Gaucher disease?
The April 2023 DailyMed label (prescribing information revised August 2022) gives 100mg orally three times a day at regular intervals in adults. It may be necessary to reduce to 100mg once or twice a day in some patients because of adverse reactions such as tremor or diarrhea. A missed dose is skipped and the next capsule taken at the next scheduled time.
How is Zavesca adjusted for renal impairment?
Start at 100mg twice a day for adjusted creatinine clearance 50 to 70mL/min/1.73m² and 100mg once a day for 30 to 50mL/min/1.73m², per section 2.2 of the April 2023 label. Use is not recommended below 30mL/min/1.73m². The effect of hemodialysis has not been investigated, and the label has no hepatic impairment study.
What monitoring does the Zavesca label require?
Neurological evaluation at baseline and at approximately 6-month intervals in all patients, per section 5.1 of the April 2023 label. Platelet count monitoring is recommended in type 1 Gaucher disease. Tremor (about 30%) and diarrhea and weight loss (about 85% and up to 65%) are managed clinically, with dose reduction for tremor.
What does the Zavesca label say about pregnancy and male fertility?
May cause fetal harm based on animal data, and breastfeeding is not recommended, per sections 8.1 and 8.2 of the April 2023 label. Section 8.3 reports no effect on male fertility in 7 healthy men treated for 6 weeks, and reversible decreased fertility in male rats. The US label sets no contraception requirement and no pregnancy testing schedule.
What are the Zavesca prior authorization criteria?
The Cigna policy shown here, IP0446 effective July 15, 2026, approves 1 year for type 1 Gaucher disease with documented deficient beta-glucocerebrosidase activity or biallelic pathogenic GBA variants. It also requires no use for neurological manifestations and a specialist prescriber. Brand Zavesca requires a trial of generic miglustat and a formulation-related reason it cannot be taken.
Free email alert
Get an email when the Zavesca label changes
One email the day the FDA revises the Zavesca prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Zavesca only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- Label: ZAVESCA- miglustat capsule (updated April 20, 2023, SPL version 19, prescribing information revised 8/2022), Actelion Pharmaceuticals US, Inc., via DailyMed, 2023-04-20.
- ZAVESCA® (miglustat): For the treatment of type 1 Gaucher Disease, Patient Resources page, Johnson & Johnson (Actelion Pharmaceuticals US, Inc.), 2026-11.
- About - ZAVESCA® (miglustat): For the treatment of type 1 Gaucher Disease, Johnson & Johnson (Actelion Pharmaceuticals US, Inc.), 2026-11.
- ZAVESCA® (miglustat): For the treatment of type 1 Gaucher Disease, Contact us page, Johnson & Johnson (Actelion Pharmaceuticals US, Inc.), 2026-11.
- Healthy Choices (ZAVESCA patient brochure, cp-115038v3, 06/25), Johnson & Johnson, 2025-06.
- Gaucher Disease - Substrate Reduction Therapy - Miglustat, Drug Coverage Policy IP0446, Cigna, 2026-07-15.
- NDA 021348/S-016 supplement approval letter, Pregnancy and Lactation Labeling Rule updates to the Prescribing Information and Patient Information, FDA, 2020-12-08.
- NDA 021348/S-15 supplement approval letter, Tallman lettering on the carton and foil blister pack, FDA, 2019-06-26.
A reference drawn from the April 20, 2023 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 11, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.